merger & acquisition
Healthcare

Quest Completes Acquisition of PathAI Diagnostics

Secaucus-based Quest Diagnostics has completed its acquisition of PathAI Diagnostics from PathAI, with the goal to accelerate the adoption of AI and digital pathology to improve the diagnosis of cancer and other diseases.

PathAI remains an independent company, dedicated to advancing AI and digital pathology solutions for biopharmaceutical companies and pathology laboratories. The transaction will support its strategy to scale its investments in AI technology and expand its software and algorithm business.

In connection with the acquisition, the PathAI Diagnostics state-of-the-art digitized laboratory in Memphis has been rebranded as AmeriPath and will act as the national AI and digital R&D and solutions center supporting Quest’s specialty pathology businesses, AmeriPath and Dermpath Diagnostics. PathAI will continue to maintain a separate research laboratory at the same site in Memphis, Tennessee to support its biopharmaceutical clients.

In addition, PathAI and Quest have formed separate agreements to further accelerate the adoption of AI and digital pathology based on their strengths and scale. Specifically, Quest will license PathAI’s AISight™ digital pathology image management system to support Quest’s pathology laboratories and customer sites in the United States. Quest is also a preferred partner of lab services for PathAI’s biopharmaceutical clients. In addition, PathAI and Quest may also collaborate on developing AI algorithms with potential research and clinical applications.

To access more business news, visit NJB News Now.

Related Articles: